<DOC>
	<DOCNO>NCT02004392</DOCNO>
	<brief_summary>This 26-week , randomized extension Phase 3 double-blind placebo-controlled study , EVP-6124-024 EVP-6124-025 . In extension study , subject complete study EVP-6124-024 EVP-6124-025 fulfill entry criterion randomize receive EVP-6124 additional 26 week .</brief_summary>
	<brief_title>Study Safety Clinical Effects 2 Doses EVP-6124 Subjects With Alzheimer 's Disease Who Complete Study EVP-6124-024 EVP-6124-025</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Male female subject race , age ≥55 ≤85 year time entry study EVP6124024 EVP6124025 Informed consent form ( ICF ) extension study sign subject legally acceptable representative ICF sign support person/caregiver initiation studyspecific procedure Successful completion ( Day 182 ) study EVP6124024 EVP6124025 No clinically significant change judgment investigator subject 's medical status study EVP6124024 EVP6124025 In judgment investigator , extension treatment best interest subject Fertile , sexually active subject ( men woman ) must use effective method contraception study . Female subject female partner male subject must surgically sterile ( hysterectomy bilateral tubal ligation ) , postmenopausal least 1year , willing practice adequate method contraception childbearing potential ( defined consistent use combine effective method contraception [ include least 1 barrier method ] ) Reliable capable support person/caregiver , live household , interacts subject approximately 4 time per week available attend clinic visit person possible Significant risk suicidal violent behavior judgment investigator Adverse event previous study ( EVP6124024 EVP6124025 ) resolve , moderate severe , judge possibly relate related study drug , consider investigator contraindication extension study participation Any condition would make subject judgment investigator unsuitable study Female subject pregnant , nursing , plan become pregnant extension study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Cognition</keyword>
	<keyword>Alpha-7 nAChR</keyword>
</DOC>